The actions, localization, and regulation of activin in the human ovary are unknown. Therefore, the aims of this study were (a) to define the effects of recombinant activin-A and its structural homologue, inhibin-A, on mitogenesis and steroidogenesis (progesterone secretion and aromatase activity) in human preovulatory follicular cells; (b) to localize the activin-A dimer in the human ovary by immunohistochemistry; and (c) to examine regulation of intracellular activin-A production in cultured human follicular cells. In addition to stimulating mitogenic activity, activin-A causes a dose-and time-dependent inhibition of basal and gonadotropin-stimulated progesterone secretion and aromatase activity in human luteinizing follicular cells on day 2 and day 4 of culture. Inhibin-A exerts no effects on mitogenesis, basal or gonadotropin-stimulated progesterone secretion and aromatase activity, and does not alter effects observed with activin-A alone. Immunostaining for dimeric activin-A occurs in granulosa and cumulus cells of human ovarian follicles and in granulosa-lutein cells of the human corpus luteum. cAMP, and to a lesser degree human chorionic gonadotropin and folliclestimulating hormone, but not inhibin-A, activin-A, or phorbol 12-myristate 13-acetate, increased the immunostaining for activin-A in cultured granulosa cells. These results indicate that activin-A may function as an autocrine or paracrine regulator of follicular function in the human ovary. (J. Clin. Invest. 1992. 
Introduction
Intragonadal peptides, in addition to the pituitary gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone, play a major role in the control of ovarian function during fetal and postnatal life (1, 2) . The Receivedforpublication 24 May 1991 and in revisedform 8 October 1991.
1. Abbreviations used in this paper: FSH, follicle-stimulating hormone;
hCG, human chorionic gonadotropin; TGF-#l, transforming growth factor-,B.
inhibin also may directly regulate intraovarian processes (4-1 1). These direct effects ofactivin and inhibin on ovarian function appear to depend upon species and experimental conditions. We reported recently that activin-A increases proliferation of cultured human preovulatory luteinizing ovarian follicular cells in a dose-and time-dependent fashion (12) . However, little is known about the effects of activin on steroidogenesis or the effects ofactivin's structural homologue, inhibin, on proliferation and steroidogenesis of human ovarian cells.
The structurally related activin and inhibin dimers were first isolated from ovarian follicular fluid (3) . Activins are composed of two homologous but distinct ,B-subunits, ,BA and ,B (activin-A [13A/13Al, activin-AB [flA/fBfi, and activin-B [#B/ 3B]J) (3, 13) and inhibins are composed of an a-subunit linked to either ofthe two 13-subunits (inhibin-A [a/13Al and inhibin-B
[a/3B]) by disulfide bridges (3, 13) . Only the intact activin and inhibin dimers exhibit biological activity. Due to the lack of antibodies specific for the activin and inhibin dimers, localization of these dimers in the ovary previously was deduced from immunostaining for the individual subunits, or from in situ and Northern blot hybridizations for the subunit mRNAs. Using these techniques, it was found that the subunits of activins and inhibins and their mRNAs are expressed during the menstrual cycle in ovarian follicular cells in a variety of species (13) (14) (15) (16) (17) (18) (19) . However, the detection ofthe subunits may reflect the presence of the biologically active dimers of either activin or inhibin or free monomeric precursors. Thus, definitive evidence for the cellular location of activin dimers in the ovary and their regulation has been lacking.
In this study, we determined the steroidogenic and mitogenic effects of recombinant human activin-A and inhibin-A on cultured human luteinizing ovarian follicular cells. We also examined the cellular localization of immunoreactive dimeric activin-A in human ovarian cells by immunocytochemistry, using a recently prepared monoclonal antibody directed against the intact, human activin-A dimer. Finally, using the same immunocytochemical technique, we examined which trophic agents regulate cellular accumulation of immunoreactive dimeric activin in dispersed cultured human luteinizing ovarian follicular cells.
Methods
Materials. Medium 199 supplemented with Earle's balanced salt solution, glutamine, gentamicin, fetal bovine serum, and saline with 0.05% trypsin-verseine were obtained from the Cell Culture Facility, University of California, San Francisco (UCSF). Collagenase-dispase human transforming growth factor-f3, and monoclonal antibodies against intact activin-A were provided by Genentech (South San Francisco, CA).
Cell culture. Human luteinizing granulosa cells were obtained by follicular aspiration from regularly menstruating women undergoing ovum retrieval for in vitro fertilization performed because of tubal obstruction. Follicular development had been stimulated by human menopausal gonadotropins (Serono Laboratories, Inc., Randolph, MA) in the presence ofa GnRH analogue (Lupron; TAP Pharmaceuticals, North Chicago, IL) until adequate response was achieved. The criteria for adequate response included three follicles > 14 mm with at least one follicle > 16 mm and an estradiol concentration > 600 pg/ml, which was increasing daily. Final maturation of the oocytes was effected with 10,000 IU human chorionic gonadotropin (hCG; Serono Laboratories). Retrieval was accomplished 35 h after the injection. Granulosa cells aspirated from follicles > 15 mm in diameter were used in the study. Cells were washed twice with medium M-199. Granulosa cells and red blood cells were transferred to a 12-ml tube containing 3.5 ml Ficoll-Paque and separated by centrifugation at 600 g for 5 min. Granulosa cells formed a thin layer between the upper phase (culture medium) and lower phase (Ficoll-Paque), while red blood cells settled to the bottom of the tube. Granulosa cells were dispersed by gentle shaking at 370C for 30 min in 5 ml culture medium containing 0.1% collagenase-dispase and 20 mg DNase/ml. The dispersed cells were washed in culture medium, counted, and plated at a density of 10,000-50,000 cells/well in 24 multiwell plates. Cells were cultured at 370C in 95% air, 5% CO2 with or without recombinant human activin-A or recombinant human inhibin-A (1-300 ng/ml). Medium was changed every other day. Cell number in each well was determined with a Coulter Counter (Coulter Corp., Hialeah, FL) after trypsinization. For immunocytochemical studies, luteinizing follicular cells were cultured on 8-well Lab-Tek plates (Nunc Inc., Naperville, IL) at a density of 2,000-5,000 cells per well for 48-96 h.
The culture medium for proliferation experiments consisted of medium M-199 containing 10% fetal bovine serum, 2 mM glutamine, and 50 mg/ml gentamicin. Cell number was assessed by Coulter Counter on days 4-6 of culture. Culture medium for determination of progesterone secretion consisted of medium M-199 containing 0.1% human serum albumin (Baxter Healthcare Corp., Glendale, CA), 2 mM glutamine, and 50 mg/ml gentamicin. The spent medium was frozen at -20°C until assayed. Progesterone was measured directly from the medium by radioimmunoassay as described previously from these laboratories (20) . For the assessment of aromatase activity, 10-6 M androstenedione was added as precursor to the culture medium and the spent medium was assayed for 17-f3 estradiol by RIA as described previously (21, 22) .
Tissue preparation. Human ovaries were obtained immediately after oophorectomy performed under general anesthesia in reproductive age women. Human tissue was removed for nonovarian disease and used in accordance with guidelines ofthe Human and Environmental Protection Committee, UCSF.
Monoclonal antibodies and absorption control. Monoclonal antibodies specific for activin-A were produced using the mutant hypogonadal mouse (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Mice were hyperimmunized in the hind foot pad with 5 ,g doses of purified recombinant activin-A. Inguinal and popliteal node lymphocytes were fused with a mouse myeloma cell line, as described previously (23) . Production of antibodies by the resulting hybridomas was assessed by solid-phase ELISA. Specificity was checked by a subsequent solid-phase ELISA using inhibin-A as the coat antigen. In brief, each well of a 96-well plate was coated overnight at 4°C with 100 ng of either recombinant activin-A or recombinant inhibin-A in 100 JAI PBS.
The plate was washed once with PBS, 0.05% Tween-20 and then blocked with PBS, 0.5% BSA for 1 h at room temperature. The antibody was serially diluted twofold in blocking buffer, then 100-,d aliquots were transferred to the plate. After a 2-h incubation at room temperature, the plate was washed six times with PBS, 0.05% Tween-20, and then 100 !il of a 1:1,000 dilution of horseradish peroxidase anti-mouse IgG was added to each well. After an additional 2-h incubation, the plate was again washed six times. Bound horseradish peroxidase was detected by standard development with o-phenylenediamine and hydrogen peroxide, followed by addition ofsulfuric acid to stop the reaction. Absorbance was measured at 490 nm with subtraction of a reference absorbance at 405 nm (Fig. 1) . The specificity was further characterized by testing immunoprecipitation of metabolically labeled activin-A and inhibin-A, produced as described previously (24) . The antibody used in the present studies did not cross-react with inhibin in either of these methods.
Specificity of the monoclonal antibody to intact activin-A was also tested by Western blot. (A monomer was generated by reducing intact, dimeric activin-A with 5% fl-mercaptoethanol at 550C for 60 min.
Monoclonal antibody reacted with intact activin-A dimer, showing a single band at 24,000 but there was no detectable band in the lane containing the monomeric subunit. Thus, no cross-reactivity was observed between the monoclonal antibody for activin-A and either inhibin-A or f3A monomer.
To test for specificity of the immunohistochemical staining, we initially attempted to absorb the antibody with activin-A in solution. However, activin has limited solubility at neutral pH and we were not able to achieve adequate concentrations. Therefore, we used a solidphase absorption. Activin-A was coated onto a 96-well plate (2 yg/well) overnight at 40C. All subsequent incubations were performed at room temperature. The plate was blocked with 5% BSA for 1 h. The antibody was diluted to 10 Ag/ml and 0.1-ml aliquots were added to the top 12 wells of the plate. Similar aliquots were added to a plate that had been coated with the activin-A diluent as a control. At 1-h intervals the aliquots were transferred to the next row down. After the material had reached the bottom row, it was collected and pooled.
Histology and immunohistochemistry. For immunocytochemistry, the ovaries and cultured cells were immersion fixed for at least 48 h in phosphate-buffered 4% paraformaldehyde. The whole tissue blocks were embedded in paraffin, and serial sections (10-Mm thick) were mounted two or three per gelatin-subbed microscope slide. Slides were deparaffinized in graded ethanols and hydrated to 0.1 M Tris-saline buffer, pH 7.4, immediately before staining.
Sections and fixed cells were pretreated with 1% H202 for 20 min. The tissue was incubated for 1-12 h with a monoclonal antibody raised against the activin-A dimer at a concentration of2-10 ,g/ml. Immunohistochemical staining was completed using the Vectastain Elite ABC Kit (Vector Lab, Inc., Burlingame, CA) with diaminobenzidine as the chromogen. No immunopositive staining was observed in control sections reacted either with absorbed antiserum or with normal mouse serum (1:500) in place of the primary antiserum used. Tissue sections were then dehydrated in graded ethanols, cleared in xylene, and mounted with Protexx (Scientific Products, McGraw Park, IL). Photographs were taken with Kodak Technical Pan film (ASA 100). 
Results
Effects ofactivin-A on steroidogenesis. Activin-A significantly decreased basal progesterone secretion on days 2 and 4 of culture. The decrease was dose-and time-dependent (Figs. 2 and  3 ). Maximal inhibition of basal progesterone secretion by 95±2% (mean±SE) was seen on day 4 ofculture. Concomitant exposure to hCG and activin-A decreased hCG-stimulated progesterone secretion in a dose-dependent manner (Fig. 3) . Addition of 600 IU/liter ofhCG increased basal progesterone secretion significantly (400% of control) (Fig. 4) .
Activin-A inhibited both basal (maximal decrease of 32±10% on day 2 and 81±20% on day 4) (Fig. 5) as well as FSH-stimulated (600 IU/liter) aromatase activity (Fig. 6 ). This inhibition was in contrast to the observed stimulatory effects on FSH-stimulated aromatase activity of transforming growth factor-3 (TGF-f3; 200 pM), a structural homologue ofactivin-A (Fig. 6) .
Effects ofinhibin-A on mitogenesis and steroidogenesis. In contrast to activin-A, the addition ofrecombinant human inhibin-A at doses of28-2,800 pM did not effect mitogenesis, basal or gonadotropin-stimulated progesterone secretion, nor aromatase activity. As we reported previously (12), addition of activin-A resulted in an increase in cell number on day 4 of culture. The addition ofinhibin-A (28-2,800 pM) to wells containing activin-A (3,600 pM) did not change the mitogenic effects observed with activin-A alone (Fig. 7) . Similarly, addition of inhibin-A to wells treated with activin-A did not alter the inhibitory effect on progesterone secretion and aromatase activity seen with activin-A alone.
Immunocytochemistry. In all specimens examined, granulosa cells of primary and secondary ovarian follicles located near the surface ofthe ovary immunostained for activin-A (Fig.  8 A) . Staining was limited to the granulosa cell cytoplasm and was granular in appearance. Activin-A also was present in granulosa cells and cumulus cells oftertiary preovulatory follicles ( Fig. 8 B, C, D Dispersed human ovarian follicular cells stained positively for the activin-A dimer (Fig. 9 A) . After treatment with 8-BrcAMP, cytoplasmic retraction and development of cellular pseudopods were observed (Fig. 9 B) . Cells stimulated with 8-Br-cAMP (1 mM) showed a marked increase in staining intensity for the immunoactive activin-A dimer (Fig. 9 B) . Staining intensity of the cells was augmented to a lesser degree by hCG (600 IU/liter) and hFSH (600 IU/liter) but not by inhibin (2,800 pM), activin-A (4,000 pM), and a phorbol ester analogue (phorbol 12-myristate 13-acetate) (10 pM) (data not shown).
Discussion
Our study demonstrates that recombinant human activin-A, but not recombinant human inhibin-A, can modulate steroidogenesis and mitogenesis in dispersed cultured human luteinizing ovarian follicular cells. Activin-A decreased basal and gonadotropin-stimulated progesterone secretion and aromatase activity in a dose-and time-dependent manner (Figs. 2-6 ). In contrast to these effects of activin-A on steroidogenesis, TGF- fl, a structural homologue of activin-A, increased FSH-stimulated aromatase activity. We did not observe any effects of inhibin-A on basal or gonadotropin-stimulated progesterone secretion and aromatase activity, or on proliferation of human luteinizing follicular cells.
In this study, we also demonstrated that immunoreactive activin-A dimer is present in follicular cells and in the corpus luteum ofthe human ovary. In our immunocytochemical studies, we used a monoclonal primary antibody that preferentially binds to activin-A but not to activin-B or inhibin. Immunopositive staining for dimeric activin-A was detected in granulosa cells ofprimary and secondary follicles as well as in granulosa and cumulus cells of large preovulatory follicles. In addition, the activin-A dimer was found in granulosa-lutein but not theca-interstitial cells of the human corpus luteum. Although inhibin/activin subunits and their mRNAs have been demonstrated in ovarian follicular cells of several species, different cellular localizations ofthese subunits have been described (15, 18, 19, (25) (26) (27) (28) . Despite a few reports to the contrary, the 13A-subunit mRNA, and therefore the potential for production of activin-A dimer, was present in large preovulatory follicles of rat (18, 26, 29) , ovine (27) , bovine (19, 27) , and monkey ovaries (28) , and in corpora lutea of monkey (28) and human (15) ovaries. Since the mere presence of either the ,3A-subunit or its mRNA provides no information on whether activin-A dimer in the human ovary is present in these cells, our results are the first to indicate that follicular granulosa and corpus luteum cells actually contain immunoreactive activin-A.
Our data further indicate that the accumulation ofthe activin dimer in dispersed cultured human luteinizing follicular cells is modulated by gonadotropins and their cellular second (9, 32) . The activin binding sites had affinity constants of 1.4 and 3.4 x 10'1, respectively (9, 32) with an estimated receptor content of 4,000 binding sites per cell. Neither TGF-j3 nor inhibin displaced activin from its receptor. These binding data correlate well with the effective dose range ofactivin which we found in human cells and which others have found in rat and bovine cells (6, 8, 11, 12, 33) . Since activin acts on pituitary cells at somewhat lower concentrations, these results suggest a lower sensitivity of ovarian versus pituitary cells to activin. The ovary seems to be one of the principal sources ofactivin and intraovarian activin concentrations may be higher than in the circulation. The lower sensitivity to activin therefore may be necessary for its intragonadal action.
Second, activin-A modulates steroidogenesis and proliferation of ovarian cells in vitro (4-6, 8, 12, 34) and in vivo (10) . It seems that the effects of activin on steroidogenesis in ovarian follicular cells depend on cells that are derived from immature follicles or from large preovulatory, mature follicles. Activin-A augments progesterone secretion and FSH-stimulated aromatase activity and induces FSH and luteinizing hormone receptors in undifferentiated granulosa cells from ovaries of immature rats (4) (5) (6) 8) . In contrast to these observations and consonant with the results of our study, activin-A inhibits progesterone secretion and prevents the spontaneous luteinization of granulosa cells from large preovulatory bovine follicles (1 1 w w _ _ã f t e r solid phase-adsorbed activin-A antibody + S i r _ĩ s substituted for the primary antiserum in the i E g -> y ! Kp r o c e d u r e . (F) A developing tertiary follicle t i e ; * s i t 9 ;s t a i n e d for activin-A dimer. Note the large nu-} t t i C F < 2 , . . . . . . < r w Z . c l e u s of the oocyte surrounded by unstained (10, 12, 34, 35) . Based on all of these studies, it seems that activin-A, like its structural homologue TGF-f3, can act as either a positive or a negative modulator ofsteroidogenesis and growth depending upon the differentiated state of the cells.
The role of inhibin as an autocrine regulator of granulosa cell function has remained controversial. While some investigators have reported inhibitory effects of inhibin on FSHstimulated estrogen production in granulosa cells (36), others have not been able to confirm these results (5, 8) . We have observed no effects of inhibin-A on basal or gonadotropin-induced granulosa cell steroidogenesis or mitogenesis. Furthermore, inhibin-A did not modulate the effects seen with activin-A alone. Thus, it appears that inhibin-A does not exert specific effects on luteinizing human ovarian follicular cells under these experiments conditions. However, these cells secrete immunoreactive inhibin in response to gonadotropins (31, 37) . Therefore, cellular secretion ofhigh levels ofinhibin could lead to saturation ofinhibin receptors so that addition ofexogenous inhibin might not elicit any additional response.
In conclusion, we have shown that activin-A modulates steroidogenesis and mitogenesis in human luteinized follicular granulosa-luteal cells in vitro. Furthermore, immunoreactive activin-A dimer is present in follicular granulosa cells and corpus luteum cells ofhuman ovaries, and its presence in cultured human follicular cells is regulated by 8-Br-cAMP. As activin-A is present in human ovarian follicular and corpus luteum cells and as it regulates steroidogenesis and mitogenesis of human ovarian luteinizing cells in vitro, it fulfills the classical requirements for a local autocrine/paracrine regulator (38) . Therefore, we suggest that activin-A acts as a local modulator of ovarian follicular function in the human ovary.
